CSL Ltd (ASX: CSL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

CSL Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $135.01 billion
P/E Ratio 39.22
Dividend Yield 0.95%
Shares Outstanding 455.12 million
Earnings per share 5.845
Dividend per share 2.70
Year To Date Return 5.23%
Earnings Yield 2.55%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
04 Mar 2021 $1.3491 0.00% Interim 01 Apr 2021
10 Sep 2020 $1.4696 0.00% Final 09 Oct 2020
11 Mar 2020 $1.4713 0.00% Interim 09 Apr 2020
10 Sep 2019 $1.4545 0.00% Final 11 Oct 2019
13 Mar 2019 $1.2032 0.00% Interim 12 Apr 2019
11 Sep 2018 $1.2782 0.00% Final 12 Oct 2018
14 Mar 2018 $1.0050 0.00% Interim 13 Apr 2018
12 Sep 2017 $0.9153 0.00% Final 13 Oct 2017
15 Mar 2017 $0.8378 0.00% Interim 13 Apr 2017
13 Sep 2016 $0.8867 0.00% Final 07 Oct 2016
23 Mar 2016 $0.8147 0.00% Interim 15 Apr 2016
07 Sep 2015 $0.8999 0.00% Final 02 Oct 2015
16 Mar 2015 $0.7439 0.00% Interim 10 Apr 2015
08 Sep 2014 $0.6485 0.00% Final 03 Oct 2014
05 Mar 2014 $0.5888 0.00% Interim 04 Apr 2014
09 Sep 2013 $0.5698 0.00% Final 04 Oct 2013
05 Mar 2013 $0.4866 0.00% Interim 05 Apr 2013
17 Sep 2012 $0.4700 0.00% Final 12 Oct 2012
14 Mar 2012 $0.3600 0.00% Interim 13 Apr 2012
19 Sep 2011 $0.4500 4.44% Final 14 Oct 2011
08 Mar 2011 $0.3500 0.00% Interim 08 Apr 2011
13 Sep 2010 $0.4500 11.73% Final 08 Oct 2010
09 Mar 2010 $0.3500 0.00% Interim 09 Apr 2010
14 Sep 2009 $0.4000 0.00% Final 09 Oct 2009
17 Sep 2007 $0.5500 50.00% Final 12 Oct 2007
30 Aug 2005 $0.1000 17.80% Special 10 Oct 2005

CSL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About CSL Ltd

CSL Limited (CSL) is a global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines to protect public health and help people with life-threatening medical conditions live full lives.

While the company has been in operation for more than a century, CSL shares were first listed on the ASX in 1994 within the healthcare sector – today, CSL sits as one of the largest companies on the ASX. The CSL share price has risen exponentially since first listing on the ASX and is now considered a traditional growth stock – CSL is known to lift profit, year-on-year, and invest much of it back into research and development and capital expenditure.

CSL’s operational businesses include CSL Behring and Seqirus, and the company operates predominantly in Australia, the USA, Germany, the United Kingdom and Switzerland.

CSL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Jun 2021 $296.64 $1.43 0.48% 403,912 $296.51 $297.73 $294.15
10 Jun 2021 $295.21 $1.10 0.37% 567,451 $296.62 $298.97 $295.21
09 Jun 2021 $294.11 $-1.08 -0.37% 452,584 $296.88 $297.97 $293.13
08 Jun 2021 $295.19 $2.62 0.90% 887,398 $294.90 $295.99 $293.09
07 Jun 2021 $292.57 $1.20 0.41% 320,163 $292.50 $293.44 $291.14
04 Jun 2021 $291.37 $4.36 1.52% 609,020 $288.80 $292.40 $288.05
03 Jun 2021 $287.01 $0.05 0.02% 479,365 $288.71 $290.35 $286.28
02 Jun 2021 $286.96 $-1.03 -0.36% 584,971 $288.40 $289.20 $285.31
01 Jun 2021 $287.99 $-2.22 -0.76% 330,619 $289.68 $289.68 $286.43
31 May 2021 $290.21 $1.09 0.38% 621,725 $289.15 $292.87 $289.12
28 May 2021 $289.12 $0.51 0.18% 584,312 $291.28 $291.72 $287.32
27 May 2021 $288.61 $-0.25 -0.09% 1,053,744 $286.25 $290.00 $285.80
26 May 2021 $288.86 $-3.10 -1.06% 470,288 $291.61 $291.73 $288.83
25 May 2021 $291.96 $2.69 0.93% 625,930 $292.72 $292.73 $290.30
24 May 2021 $289.27 $4.97 1.75% 664,155 $284.15 $290.48 $283.65
21 May 2021 $284.30 $6.14 2.21% 1,571,606 $280.28 $284.79 $279.00
20 May 2021 $278.16 $3.71 1.35% 714,091 $274.90 $279.46 $274.73
19 May 2021 $274.45 $-2.76 -1.00% 675,333 $274.35 $277.25 $271.77
18 May 2021 $277.21 $0.64 0.23% 436,111 $279.00 $279.00 $275.65
17 May 2021 $276.57 $-1.11 -0.40% 395,838 $280.00 $280.00 $276.02
14 May 2021 $277.68 $0.17 0.06% 484,320 $275.32 $278.98 $273.67

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
23 Feb 2021 Carolyn Hewson Transfer 174 $46,625
Off-market transfer. Assuming 174 Direct shares transferred to Indirect shares.
23 Feb 2021 Carolyn Hewson Transfer 174 $46,625
Off-market transfer. Assuming 174 Direct shares transferred to Indirect shares.
23 Feb 2021 Carolyn Hewson Buy 202 $59,600
Conversion of securities.
23 Feb 2021 Carolyn Hewson Exercise 202 $59,600
Conversion of securities. 202 - Rights
23 Feb 2021 Brian McNamee Buy 278 $82,023
Conversion of securities.
23 Feb 2021 Brian McNamee Exercise 278 $82,023
Conversion of securities. 278 - Rights
23 Feb 2021 Bruce Brook Exercise 81 $23,899
Conversion of securities. 80 - Rights
23 Feb 2021 Bruce Brook Buy 81 $23,899
Conversion of securities.
23 Feb 2021 Marie McDonald Exercise 121 $35,701
Conversion of securities. 121 - Rights
23 Feb 2021 Marie McDonald Buy 121 $35,701
Conversion of securities.
23 Feb 2021 Megan Clark Exercise 81 $23,899
Conversion of securities. 80 - Rights
23 Feb 2021 Megan Clark Buy 81 $23,899
Conversion of securities.
15 Oct 2020 Paul Perreault Issued 32 $9,858,024
Issue of securities. 97,719 - Performance Share Units
21 Sep 2020 Robert Cuthbertson Transfer 89 $25,260,801
As advised by the company. Change in direct / indirect holding due to
change in custodian arrangement.
21 Sep 2020 Robert Cuthbertson Transfer 89 $25,260,801
As advised by the company. Change in direct / indirect holding due to
change in custodian arrangement.
09 Sep 2020 Robert Cuthbertson Buy 11 $3,145,795
Conversion of securities.
09 Sep 2020 Robert Cuthbertson Exercise 11 $3,145,795
Conversion of securities. 13,010 - Performance Share Units
01 Sep 2020 Robert Cuthbertson Buy 6 $1,746,979
Conversion of securities.
01 Sep 2020 Robert Cuthbertson Exercise 6 $1,746,979
Conversion of securities. 24,494 - Performance Rights & Performance Share Units
01 Sep 2020 Robert Cuthbertson Expiry 289 $81,405
As advised by the company. 24,205 - Performance Rights & Performance Share Units.
Lapsing of unvested Performance Share
Units
01 Sep 2020 Paul Perreault Sell 14 $4,092,193
On-market trade. Reported Nature of change seems typo.
01 Sep 2020 Paul Perreault Buy 31 $9,002,774
Conversion of securities.
01 Sep 2020 Paul Perreault Expiry 1 $419,984
As advised by the company. Lapsing of Performance Share Units.
64,967 - Performance Share Units
01 Sep 2020 Paul Perreault Exercise 31 $9,002,774
Conversion of securities. 66,458 - Performance Rights & Performance Share Units.
28 Aug 2020 Paul Perreault Sell 194 $56,754,116
On-market trade.
28 Aug 2020 Paul Perreault Transfer 20 $5,797,800
Off-market transfer. Assuming 20,000 Direct shares transferred to Indirect shares.
28 Aug 2020 Paul Perreault Transfer 20 $5,797,800
Off-market transfer. Assuming 20,000 Direct shares transferred to Indirect shares.
27 Aug 2020 Bruce Brook Issued 161 $47,261
Issue of securities. 161 - Rights
27 Aug 2020 Christine O'Reilly Issued 404 $119,200
Issue of securities. 404 - Rights
27 Aug 2020 Carolyn Hewson Issued 404 $118,594
Issue of securities. 404 - Rights
27 Aug 2020 Brian McNamee Issued 556 $164,047
Issue of securities. 556 - Rights
27 Aug 2020 Marie McDonald Issued 242 $71,402
Issue of securities. 242 - Rights
27 Aug 2020 Megan Clark Issued 161 $47,503
Issue of securities. 161 - Rights
27 Aug 2020 Shah Abbas Hussain Issued 161 $47,503
Issue of securities. 572 - Rights
27 Aug 2020 Pascal Soriot Issued 139 $41,011
Issue of securities. 139 - Rights
26 Aug 2020 Paul Perreault Exercise 163 $17,536,876
Exercise of options.
26 Aug 2020 Paul Perreault Exercise 50 $14,793,787
Conversion of securities. 98,419 - Performance Share Units
26 Aug 2020 Paul Perreault Buy 50 $14,793,787
Conversion of securities.
26 Aug 2020 Paul Perreault Buy 163 $17,536,876
Exercise of options.
25 Aug 2020 Shah Abbas Hussain Buy 340 $100,160
On-market trade.
24 Aug 2020 Marie McDonald Buy 151 $34,799
Conversion of securities.
24 Aug 2020 Marie McDonald Exercise 151 $34,799
Conversion of securities.
24 Aug 2020 Megan Clark Exercise 100 $23,046
Conversion of securities.
24 Aug 2020 Megan Clark Buy 100 $23,046
Conversion of securities.
24 Aug 2020 Bruce Brook Buy 201 $46,322
Conversion of securities.
24 Aug 2020 Bruce Brook Exercise 201 $46,322
Conversion of securities.
24 Aug 2020 Christine O'Reilly Exercise 151 $34,799
Conversion of securities.
24 Aug 2020 Christine O'Reilly Buy 151 $34,799
Conversion of securities.
24 Aug 2020 Brian McNamee Exercise 346 $79,739
Conversion of securities.
24 Aug 2020 Brian McNamee Buy 346 $79,739
Conversion of securities.
24 Aug 2020 Carolyn Hewson Transfer 174 $51,350
Off-market transfer. Assuming 174 Indirect shares to Direct shares.
24 Aug 2020 Carolyn Hewson Buy 388 $129,064
Conversion of securities.
24 Aug 2020 Carolyn Hewson Transfer 174 $51,350
Off-market transfer. Assuming 174 Indirect shares to Direct shares.
24 Aug 2020 Carolyn Hewson Exercise 388 $129,064
Conversion of securities.
20 Aug 2020 Robert Cuthbertson Expiry 194 $58,200
As advised by the company. 30,696 - Performance Rights & Performance Share Units.
Lapsing of unvested Performance Rights.
20 Aug 2020 Paul Perreault Expiry 884 $265,200
As advised by the company. Lapsing of unvested Performance Rights
149,262 - Performance Share Units

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Carolyn Judith Hewson Non-Executive Director Dec 2019
Ms Hewson has over 35 years' experience in the finance sector. Ms Hewson has previously held long-term Non-Executive roles in a number of sectors, having held director appointments with Schroders Australia Limited, Stockland Group, BT Investment Management Limited, Westpac Banking Corporation, AGL Energy Limited, the Australian Gas Light Company, CSR Limited, AMP Limited, South Australian Water and the Economic Development Board of South Australia. Ms Hewson recently retired as a Non-executive Director of BHP Limited where she was Chairman of the BHP Remuneration Committee and a member of the Nomination and Governance Committee. She remains a Director of Infrastructure SA and a Member of the Federal Government Growth Centres Advisory Committee
Dr Brian Anthony McNamee Non-Executive DirectorNon-Executive Chairman Jan 1990
Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee has a global perspective and understanding of long-term capital projects in the pharmaceutical industry, with proven health, safety, environment and corporate responsibility. Dr McNamee has served as a Senior Advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is also a Chairman of GenesisCare Limited.He is also Chairman of the Innovation and Development Committee and member of of the Corporate Governance.
Dr Robert Andrew Cuthbertson Non-Executive Director Oct 2018
Dr Cuthbertson has over 35 years experience in medical research and biotech development with large biopharmaceutical companies and medical organisations. He also has non-executive director experience. Prior to CSL, he was a Senior Scientist at Genentech Inc, a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life-threatening diseases. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is also a Director of the Centre of Eye Research Australia and Director of the Grattan Institute. He is also a member of the Innovation and Development Committee.
Mr Bruce Robert Brook Non-Executive Director Aug 2011
Mr Brook has executive experience in industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was Chief Financial Officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including Deputy Chief Finance Officer of ANZ Banking Group Limited, Group Chief Accountant of Pacific Dunlop Limited and General Manager, Group Accounting positions at CRA Limited and Pasminco Limited. He is also a Director of Newmont Goldcorp Corporation; Director of Incitec Pivot Limited; Director of Guide Dogs Victoria; Former Director and Chairman of Programmed Group; and Former Director of the Deep Exploration Technologies Co-operative Research Center Limited. He is also Chairman of the Risk Management Committee and member of the Corporate Governance.
Mr Paul Perreault Executive DirectorChief Executive OfficerManaging Director Feb 2013
Mr Perreault has more than 35 years of experience across both the global biotech and pharmaceutical industries. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer.
Ms Marie Elizabeth McDonald Non-Executive Director Aug 2013
Ms McDonald has executive and non-executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a Member of the Australian Takeovers Panel for nine years. She is a Director of Nanosonics Limited (since October 2016); Director of Nufarm Limited (since March 2017); and Director of the Walter & Eliza Hall Institute of Medical Research (since October 2016). She is also a member of the Risk Management Committee, Member of the Human Resources.
Dr Megan Elizabeth Clark Non-Executive Director Feb 2016
Dr Clark has executive and non-executive experience across a range of sectors including scientific research, health, investment banking and financial services, education and mining. Dr Clark brings a strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. Dr Clark was Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a Director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including Vice President Technology and Vice President Health, Safety and Environment. She is also a Director of Rio Tinto Limited and Rio Tinto Plc; Director of Care Australia Limited; member of the Australian advisory board of the Bank of America Merrill Lynch (since July 2010);member of Council of Monash University Council; and Head of the Australian Space Agency. She is also Chairman of the Human Resources; Member of the Corporate Governance committee,Innovation and Development Committee.
Mr Shah Abbas Hussain Non-Executive Director Feb 2018
Mr Hussain has executive experience in the biopharmaceutical industry and biotechnology industry insight. Through his executive and non-executive roles, Mr Hussain has a global perspective and understanding of pharmaceutical manufacturing, product development, risk, health, safety, environment and corporate responsibility. Mr Hussain was the Global President, Pharmaceutical at GlaxoSmithKline (GSK) serving from 2008 to late 2017, where he managed a global pharmaceutical and vaccine business across 150 markets including the US, Europe, Japan and emerging markets. Before GSK he held senior roles with global responsibilities at Eli Lilly. He is also Director of Immunocore Limited (since May 2017); Director of Cochlear Limited (since December 2018); Senior Advisor on the Advisory Board of CellResearch Corporation (since August 2017); Senior Advisor at C-Bridge Capital (since October 2017); and Former Director of ViiV Healthcare Limited (from October 2009 to July 2017). He is a member of the Innovation and Development Committee, Member of the Human Resources Committee.
Ms Fiona Mead Company SecretaryHead of Group Governance Jun 2018
-
Fiona Mead Company SecretaryHead of Group Governance
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 154,130,927 33.95%
J P Morgan Nominees Australia Pty Limited 81,317,162 17.91%
Citicorp Nominees Pty Limited 33,409,768 7.36%
National Nominees Limited 12,932,543 2.85%
BNP Paribas Nominees Pty Ltd 7,884,394 1.74%
Bnp Paribas Noms Pty Ltd 5,625,521 1.24%
Citicorp Nominees Pty Limited I 4,314,290 0.95%
Hsbc Custody Nominees (Australia) Limited I 2,547,501 0.56%
Australian Foundation Investment Company Limited 2,012,754 0.44%
Netwealth Investments Limited 1,499,000 0.33%
Custodial Services Limited 1,386,344 0.31%
Solium Nominees (Australia) 1,365,798 0.30%
Argo Investments Limited 1,113,370 0.25%
Hsbc Custody Nominees (Australia) Limited II 866,277 0.19%
Hsbc Custody Nominees (Australia) Limited III 857,419 0.19%
D W S Nominees Pty Ltd 793,090 0.17%
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 724,197 0.16%
Amp Life Limited 704,273 0.16%
Mutual Trust Pty Ltd 652,588 0.14%
Navigator Australia Ltd 608,222 0.13%

Frequently Asked Questions

CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks the company has embarked on, the adjusted entry price is equivalent to around 76 cents. Given CSL’s current share price, original shareholders would be very pleased!

CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent with all dividends since 2012 having been unfranked. CSL paid an interim dividend of $1.47 on 9 April 2020 and is scheduled to pay its final dividend early to mid-October.

CSL has a dividend reinvestment plan however it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.

Profile

since

Note